Zhonghua Zhong Liu Za Zhi. 2021 Oct 23;43(10):1001-1006. doi: 10.3760/cma.j.cn112152-20210809-00597.
Human epidermal growth factor receptor 2 (HER-2) plays an important role in carcinogenesis and development of urothelial carcinoma. Overexpression of HER-2 is associated with poor prognosis of urothelial carcinoma. Although there is no significant benefit from anti-HER-2 targeted therapies of monoclonal antibody and tyrosine kinase inhibitor, Anti-HER-2 antibody-drug conjugate (HER-2-ADC) has shown a promising efficacy in urothelial carcinoma patients with HER-2 overexpression. Therefore, effectively screening the potential beneficiaries of HER-2-ADC drugs has become a new challenge. However, standardized HER-2 scoring system for urothelial carcinoma has yet to be developed. Thus, the Committees organized experts to reach this expert consensus based on the clinical practice of HER-2 expression, gene amplification and mutation testing in urothelial carcinoma, combined with the current research progress and internal discussion of committee members, in order to construct HER-2 testing standard of urothelial carcinoma and improve the accuracy of interpretation, to guide the clinical application.
人表皮生长因子受体2（HER-2）在尿路上皮癌的发生和发展中起重要作用。HER-2过表达与尿路上皮癌的预后不良相关。尽管抗HER-2单克隆抗体和酪氨酸激酶抑制剂靶向治疗未显示出显著益处，但抗HER-2抗体药物偶联物（HER-2-ADC）在HER-2过表达的尿路上皮癌患者中已显示出有前景的疗效。因此，有效筛选HER-2-ADC药物的潜在受益患者已成为一项新挑战。然而，尿路上皮癌的标准化HER-2评分系统尚未建立。因此，委员会组织专家根据尿路上皮癌HER-2表达、基因扩增和突变检测的临床实践，结合当前研究进展及委员会成员内部讨论，达成该专家共识，以构建尿路上皮癌HER-2检测标准并提高解读准确性，指导临床应用。
